Numinus Wellness Inc (TSE:NUMI) has released an update.
Numinus Wellness Inc. has announced that Cedar Clinical Research will participate in Cybin’s Phase 3 clinical trial of CYB003 for Major Depressive Disorder, following a successful Phase 2 trial that saw 75% remission in symptoms. The trial will investigate the treatment’s safety and efficacy, with FDA breakthrough therapy designation potentially accelerating its development. Numinus is optimistic about the role of psychedelic-assisted therapy in mental health care and is preparing for the trial’s commencement in mid-2024.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.
